Perrigo Company plc Reports Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
BofA/Merrill Lynch Upgrades Perrigo Co. (PRGO) to Neutral
November 11, 2016 6:43 AM ESTBofA/Merrill Lynch upgraded Perrigo Co. (NYSE: PRGO) from Underperform to Neutral.
For an analyst ratings summary and ratings history on Perrigo Co. click here. For more ratings news on Perrigo Co. click here.
Shares of Perrigo Co. closed at $89.11 yesterday.
... MorePerrigo (PRGO) Tops Q3 EPS by 7c; Will Explore Strategic Alternatives for Tysabri
November 10, 2016 6:23 AM ESTPerrigo (NYSE: PRGO) reported Q3 EPS of $1.65, $0.07 better than the analyst estimate of $1.58. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.28 billion.
Perrigo also announced that as part of its ongoing business portfolio review, the Company will review strategic alternatives for the rights to the royalty stream from sales of the multiple sclerosis drug Tysabri® (natalizumab).
Perrigo's CEO... More
